A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Clinical trial NCT07495215 · RECRUITING
Trial details
- NCT number
- NCT07495215
- Sponsor
- Yinghua Xu
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-11
- Primary completion
- 2028-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.